Regulatory approval

Published by the Health Service Executive. Approved

Quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Quizartinib: CDS; Daunorubicin, Cytarabine: N/A

Citation

Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy, 2026, version number 2, viewed 02/08/2026, https://healthservice.hse.ie/documents/7017/886_Quizartinib_Induction_DAUNOrubicin.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Quizartinib

Contributions

Date Contributor Description
2025-02-01 Health Service Executive Indication approved for reimbursement.
2024-01-16 Van Allen lab Adding HSE approvals for reimbursement to database